Literature DB >> 30927210

Integrin Calculus: The Predictive Power of Vedolizumab Concentrations in IBD Therapy.

Konstantinos Papamichael1, Adam S Cheifetz2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30927210     DOI： 10.1007/s10620-019-05601-x

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  8 in total

1.  Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases.

Authors:  Erwin Dreesen; Bram Verstockt; Sumin Bian; Magali de Bruyn; Griet Compernolle; Sophie Tops; Maja Noman; Gert Van Assche; Marc Ferrante; Ann Gils; Séverine Vermeire
Journal:  Clin Gastroenterol Hepatol       Date:  2018-04-25       Impact factor: 11.382

2.  Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance.

Authors:  Claire Liefferinckx; Charlotte Minsart; Anneline Cremer; Leila Amininejad; Vjola Tafciu; Eric Quertinmont; Sophie Tops; Jacques Devière; Ann Gils; André van Gossum; Denis Franchimont
Journal:  Eur J Gastroenterol Hepatol       Date:  2019-04       Impact factor: 2.566

3.  Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases.

Authors:  Andres J Yarur; Alexandra Bruss; Snehal Naik; Poonam Beniwal-Patel; Caroline Fox; Anjali Jain; Brandon Berens; Amir Patel; Ryan Ungaro; Bayda Bahur; Marla Dubinsky; Daniel J Stein
Journal:  Dig Dis Sci       Date:  2019-03-05       Impact factor: 3.199

4.  Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months.

Authors:  Nicolas Williet; Gilles Boschetti; Marion Fovet; Thomas Di Bernado; Pierre Claudez; Emilie Del Tedesco; Camille Jarlot; Leslie Rinaldi; Anne Berger; Jean-Marc Phelip; Bernard Flourie; Stéphane Nancey; Stéphane Paul; Xavier Roblin
Journal:  Clin Gastroenterol Hepatol       Date:  2016-11-24       Impact factor: 11.382

Review 5.  Use of anti-TNF drug levels to optimise patient management.

Authors:  Konstantinos Papamichael; Adam S Cheifetz
Journal:  Frontline Gastroenterol       Date:  2016-02-26

6.  Vedolizumab Trough Levels and Histological Healing During Maintenance Therapy in Ulcerative Colitis.

Authors:  Lieven Pouillon; Hélène Rousseau; Hélène Busby-Venner; Marcelo De Carvalho Bittencourt; Myriam Choukour; Guillaume Gauchotte; Camille Zallot; Silvio Danese; Cédric Baumann; Laurent Peyrin-Biroulet
Journal:  J Crohns Colitis       Date:  2019-08-14       Impact factor: 9.071

7.  Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study.

Authors:  W Yacoub; N Williet; L Pouillon; T Di-Bernado; M De Carvalho Bittencourt; S Nancey; A Lopez; S Paul; C Zallot; X Roblin; L Peyrin-Biroulet
Journal:  Aliment Pharmacol Ther       Date:  2018-01-31       Impact factor: 8.171

8.  Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation.

Authors:  Mark T Osterman; Maria Rosario; Karen Lasch; Morris Barocas; Jayson D Wilbur; Nathanael L Dirks; Marc R Gastonguay
Journal:  Aliment Pharmacol Ther       Date:  2019-01-20       Impact factor: 8.171
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.